The Future of CRISPR: Looking at Gene Editing as a Treatment For Cystic Fibrosis

Authors

  • Harisha Kosanam West Chester Bayard Rustin High School
  • Ananya Udyaver West Windsor Plainsboro High School South
  • Waliya Muhammad Thomas Jefferson University

DOI:

https://doi.org/10.47611/jsrhs.v10i1.1293

Keywords:

Cystic Fibrosis, Gene Editing, CRISPR

Abstract

Cystic Fibrosis (CF) is a genetically inherited chronic disease that causes the production of a thick and sticky mucus primarily in the lungs. The condition tends to become worse over time. Clogged lungs and other internal organs result in breathing issues, susceptibility to infections, digestive problems, and lack of nutrition. CF is an autosomal recessive disease, indicating that an individual must inherit two copies of the defective Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, which then encodes for a malfunctioning CFTR protein. Because of the large number of CF patients that cannot be treated with these CFTR modulators, using gene editing to directly target the mutation can be more effective and efficient in treating cystic fibrosis. In this paper, we will discuss the promises and limitations for using gene editing as a treatment for CF.

Downloads

Download data is not yet available.

Author Biography

Waliya Muhammad, Thomas Jefferson University

Lecturer and Laboratory Instructor Thomas Jefferson University

Published

03-31-2021

How to Cite

Kosanam, H., Udyaver, A. ., & Muhammad, W. (2021). The Future of CRISPR: Looking at Gene Editing as a Treatment For Cystic Fibrosis. Journal of Student Research, 10(1). https://doi.org/10.47611/jsrhs.v10i1.1293

Issue

Section

HS Review Articles